Core Insights - China's pharmaceutical innovation capabilities are gaining global recognition, as highlighted by reports from McKinsey and BCG, which affirm the rise of innovative drugs in various fields and acknowledge the innovation quality of the domestic pharmaceutical industry [1][21][24] - The "Fierce 15" list, published by Fierce Biotech, identifies 15 innovative biotech companies, many of which have corresponding domestic counterparts, indicating the forward-looking nature of China's innovation [1][18] Group 1: AI in Drug Development - AI is becoming a crucial innovation point in drug development, with four companies in the "Fierce 15" list utilizing AI in their drug discovery processes [5][17] - Character Biosciences, established in 2019, leverages vast insurance data to develop drugs for age-related chronic diseases, utilizing AI to create a drug development platform focused on age-related macular degeneration (AMD) [5][7] - The company has raised approximately $230 million, including investments from major players like Bausch + Lomb and Sanofi [5] Group 2: Domestic AI Drug Discovery Companies - Shanghai Drug Farm, founded in 2015, focuses on discovering new drug targets using genetics and AI, with two AI platforms that have identified over 20 innovative targets [8][10] - MoleculeAI, a domestic company, is pioneering AI-driven protein design, aiming to create new proteins on demand, which could represent a new foundation for the bio-economy [14] - Domestic companies are increasingly adopting AI to optimize clinical trial processes, with examples like Deep Intelligence and WuXi AppTec enhancing efficiency through AI tools [16] Group 3: Global Recognition of Chinese Innovation - The "Fierce 15" list includes Chinese companies like Ouro Medicines and Verdiva Bio, showcasing the global reach of Chinese innovation [18][19] - BCG's report indicates that China is becoming a key growth engine in global new modalities, with over 4,000 clinical projects, ranking second globally [21] - McKinsey's analysis highlights a fundamental change in China's position in the global innovative drug industry, predicting that by 2030, China will account for 10% to 15% of new drug listings globally [24][23]